Short Interest in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Decreases By 79.5%

Posted by Stanley Muller on Aug 26th, 2026

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT – Get Free Report) was the target of a significant drop in short interest during the month of August. As of August 14th, there was short interest totaling 770 shares, a drop of 79.5% from the July 30th total of 3,749 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average trading volume of 34,611 shares, the short-interest ratio is currently 0.0 days.

Institutional Investors Weigh In On Bolt Biotherapeutics

A number of institutional investors have recently bought and sold shares of BOLT. T3 Companies LLC bought a new stake in Bolt Biotherapeutics in the 4th quarter valued at $208,000. Renaissance Technologies LLC lifted its holdings in shares of Bolt Biotherapeutics by 92.2% during the 4th quarter. Renaissance Technologies LLC now owns 55,025 shares of the company’s stock worth $301,000 after acquiring an additional 26,400 shares during the period. Nano Cap New Millennium Growth Fund L P acquired a new stake in shares of Bolt Biotherapeutics during the 4th quarter valued at about $112,000. Susquehanna International Group LLP acquired a new stake in shares of Bolt Biotherapeutics during the 3rd quarter valued at about $89,000. Finally, Shay Capital LLC acquired a new stake in shares of Bolt Biotherapeutics during the 3rd quarter valued at about $85,000. Institutional investors and hedge funds own 86.70% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on BOLT. HC Wainwright reiterated a “buy” rating and set a $7.00 target price on shares of Bolt Biotherapeutics in a research note on Thursday, May 28th. Weiss Ratings restated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research report on Friday, July 17th. Finally, Rodman & Renshaw assumed coverage on shares of Bolt Biotherapeutics in a report on Thursday, May 28th. They set a “buy” rating and a $22.00 price objective on the stock. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $14.50.

Check Out Our Latest Analysis on Bolt Biotherapeutics

Bolt Biotherapeutics Trading Down 1.7%

Bolt Biotherapeutics stock opened at $3.79 on Wednesday. The business has a 50 day moving average price of $3.91 and a two-hundred day moving average price of $4.44. The company has a quick ratio of 2.61, a current ratio of 2.61 and a debt-to-equity ratio of 1.47. Bolt Biotherapeutics has a 12 month low of $3.13 and a 12 month high of $7.20. The stock has a market cap of $7.29 million, a price-to-earnings ratio of -0.23 and a beta of 1.18.

Bolt Biotherapeutics (NASDAQ:BOLT – Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($4.57) earnings per share for the quarter, missing the consensus estimate of ($3.39) by ($1.18). The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.50 million. Bolt Biotherapeutics had a negative return on equity of 126.23% and a negative net margin of 611.47%. As a group, equities analysts forecast that Bolt Biotherapeutics will post -11.1 EPS for the current year.

Bolt Biotherapeutics Company Profile

(Get Free Report)

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.